• Explore /
  • Poster
  • / IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

Abstract Video & Slides Poster

Authors

null

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center, New York, NY

Sandra P. D'Angelo , Jonathan Christopher Noujaim , Fiona Thistlethwaite , Albiruni Ryan Abdul Razak , Silvia Stacchiotti , Warren Allen Chow , John B. A. G. Haanen , Anna Weinberg Chalmers , Steven Ian Robinson , Brian Andrew Van Tine , Kristen N. Ganjoo , Melissa L. Johnson , Victoria L. Chiou , Thomas H. Faitg , Mary Woessner , Laura Pearce , Aiman Shalabi , Jean-Yves Blay , George Demetri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT03967223

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS11582)

DOI

10.1200/JCO.2021.39.15_suppl.TPS11582

Abstract #

TPS11582

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Dejka M. Araujo

First Author: Sandra P. D'Angelo

First Author: Sandra P. D'Angelo

First Author: Dejka M. Araujo